Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. The company announced its 2024 annual results, which showed good cash on its balance sheet and reminded investors that a pivotal trial is underway.